Affiliation:
1. Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh 281406,India
Abstract
Background:
Prostate cancer is the second most common cancer worldwide. The androgen
deprivation therapy or castration leads to the recurrence of castration-resistant prostate cancer
after some time. Androgen receptor is one of the most promising targets for the treatment of prostate
cancer. The health benefits of phytoestrogens led us to explore them for their androgen receptor inhibition
potential that may lead to inhibition of initiation and progression of prostate cancer.
Methods:
Protein-ligand interaction plays a central role in structure-based drug design, so we
screened 23 phytoestrogens for their binding affinity to the androgen receptor using the molecular
docking approach. These phytoestrogens were also tested for their ADME and toxicity profiles using
the software.
Results:
Based on binding affinity, interacting amino acid residues, pharmacokinetics and toxicity
profile, four phytoestrogens, namely naringenin, luteolin, hesperetin, and biochanin A were shortlisted
as lead molecules.
Conclusion:
Therefore, our study has shown that these four phytoestrogens could be promising candidates
for further evaluation for prostate cancer treatment or management.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献